Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
167 hedge funds and large institutions have $1.32B invested in Esperion Therapeutics in 2019 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 61 increasing their positions, 40 reducing their positions, and 25 closing their positions.
85% more call options, than puts
Call options by funds: $42.3M | Put options by funds: $22.8M
53% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 40
32% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 25
19% more capital invested
Capital invested by funds: $1.11B → $1.32B (+$215M)
2.76% more ownership
Funds ownership: 102.91% → 105.68% (+2.8%)
2% more funds holding
Funds holding: 163 → 167 (+4)
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$167M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$23M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
+$18.1M |
| 4 |
State Street
Boston,
Massachusetts
|
+$9.62M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$9.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AH
Aviva Holdings
New Providence,
Bahamas
|
-$17.7M |
| 2 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$17.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$14.4M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.06M |
| 5 |
SIM
Spark Investment Management
New York
|
-$6.4M |
ESPR Hedge Fund Activity: Q2 2019 in Review
167 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q2 2019, worth a combined $1.32B — up 19% from $1.11B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new ESPR positions and 25 closed out — a net gain of 8 holders — while 61 added to existing stakes and 40 trimmed.
The largest buyer was Bellevue Group, adding an estimated $167M. The largest seller was Aviva Holdings, exiting entirely with an estimated $17.7M sold.
- 167 institutional investors held Esperion Therapeutics (ESPR) as of Q2 2019, up from 163 in Q1 2019.
- Funds reported $1.32B of Esperion Therapeutics stock for Q2 2019, up 19% quarter-over-quarter.
- 33 funds opened new Esperion Therapeutics positions in Q2 2019 and 25 closed out, a net change of +8 holders.
- The largest Esperion Therapeutics buyer in Q2 2019 was Bellevue Group, an estimated $167M added.
- The largest Esperion Therapeutics seller in Q2 2019 was Aviva Holdings, an estimated $17.7M sold.
Based on aggregated 13F filings for Q2 2019.